These highlight an “epigenetic switch,” where loss of H3K27me3 is accompanied by an increase in H3K27Ac following Ezh2 loss and leukemia-initiating cells from the Ezh2−/−/Jak2V617F mice showed sensitivity to BET inhibitors, targeting gene expression related to altered H3K27Ac (Sashida et al., 2016). The gene discussed is EZH2; the disease is leukemia.